Synopsis
Nature Medicine, Published online: 29 October 2026; doi:10.1038/d41591-026-00055-x Preclinical analysis and a phase 1 trial support VG-3927 as a promising drug candidate for Alzheimer’s disease, demonstrating successful penetration of the central nervous system, target engagement and tolerability.
The publisher’s own description. This is a short summary, not the full story, and may omit important detail.
Read the full story at Nature Medicine ↗
